


Listing of Claims:

1. (Currently Amended) ~~Benzimidazole carboxamides~~ A compound or compounds of formula I



wherein

R<sup>6</sup>, R<sup>7</sup> are independently from one another H, A or SO<sub>2</sub>A,

A is independently selected from the group consisting of alkyl, alkenyl, cycloalkyl, alkylene cycloalkyl, alkoxy and alkoxyalkyl,

Ar<sup>2</sup> is selected independently from one another from aromatic hydrocarbons containing 6 to 14 carbon atoms and ethylenically unsaturated or aromatic heterocyclic residues containing 3 to 10 carbon atoms and one or two heteroatoms, independently selected from the group consisting of N, O and S,

R<sup>8</sup>, R<sup>9</sup> and R<sup>10</sup> are independently selected from a the group consisting of H, A, cycloalkyl comprising 3 to 7 carbon atoms, Hal, CH<sub>2</sub>Hal, CH(Hal)<sub>2</sub>, C(Hal)<sub>3</sub>, NO<sub>2</sub>, (CH<sub>2</sub>)<sub>n</sub>CN, (CH<sub>2</sub>)<sub>n</sub>NR<sup>11</sup>R<sup>12</sup>, (CH<sub>2</sub>)<sub>n</sub>OR<sup>11</sup>, (CH<sub>2</sub>)<sub>n</sub>O(CH<sub>2</sub>)<sub>k</sub>NR<sup>11</sup>R<sup>12</sup>, (CH<sub>2</sub>)<sub>n</sub>COOR<sup>12</sup>, (CH<sub>2</sub>)<sub>n</sub>CONR<sup>11</sup>R<sup>12</sup>, (CH<sub>2</sub>)<sub>n</sub>NR<sup>11</sup>COR<sup>13</sup>, (CH<sub>2</sub>)<sub>n</sub>NR<sup>11</sup>CONR<sup>11</sup>R<sup>12</sup>, (CH<sub>2</sub>)<sub>n</sub>NR<sup>11</sup>SO<sub>2</sub>A, (CH<sub>2</sub>)<sub>n</sub>SO<sub>2</sub>NR<sup>11</sup>R<sup>12</sup>, (CH<sub>2</sub>)<sub>n</sub>S(O)<sub>u</sub>R<sup>13</sup>,

(CH<sub>2</sub>)<sub>n</sub>OC(O)R<sup>13</sup>, (CH<sub>2</sub>)<sub>n</sub>COR<sup>13</sup>, (CH<sub>2</sub>)<sub>n</sub>SR<sup>11</sup>, CH=N-OA,  
CH<sub>2</sub>CH=N-OA, (CH<sub>2</sub>)<sub>n</sub>NHOA, (CH<sub>2</sub>)<sub>n</sub>CH=N-R<sup>11</sup>,  
(CH<sub>2</sub>)<sub>n</sub>OC(O)NR<sup>11</sup>R<sup>12</sup>, (CH<sub>2</sub>)<sub>n</sub>NR<sup>11</sup>COOR<sup>12</sup>,  
(CH<sub>2</sub>)<sub>n</sub>N(R<sup>11</sup>)CH<sub>2</sub>CH<sub>2</sub>OR<sup>13</sup>, (CH<sub>2</sub>)<sub>n</sub>N(R<sup>11</sup>)CH<sub>2</sub>CH<sub>2</sub>OCF<sub>3</sub>,  
(CH<sub>2</sub>)<sub>n</sub>N(R<sup>11</sup>)C(R<sup>13</sup>)HCOOR<sup>12</sup>, C(R<sup>13</sup>)HCOR<sup>12</sup>,  
(CH<sub>2</sub>)<sub>n</sub>N(R<sup>11</sup>)CH<sub>2</sub>CH<sub>2</sub>N(R<sup>12</sup>)CH<sub>2</sub>COOR<sup>12</sup>,  
(CH<sub>2</sub>)<sub>n</sub>N(R<sup>11</sup>)CH<sub>2</sub>CH<sub>2</sub>NR<sup>11</sup>R<sup>12</sup>, CH=CHCOOR<sup>11</sup>,  
CH=CHCH<sub>2</sub>NR<sup>11</sup>R<sup>12</sup>, CH=CHCH<sub>2</sub>NR<sup>11</sup>R<sup>12</sup>, CH=CHCH<sub>2</sub>OR<sup>13</sup>,  
(CH<sub>2</sub>)<sub>n</sub>N(COOR<sup>11</sup>)COOR<sup>12</sup>, (CH<sub>2</sub>)<sub>n</sub>N(CONH<sub>2</sub>)COOR<sup>11</sup>,  
(CH<sub>2</sub>)<sub>n</sub>N(CONH<sub>2</sub>)CONH<sub>2</sub>, (CH<sub>2</sub>)<sub>n</sub>N(CH<sub>2</sub>COOR<sup>11</sup>)COOR<sup>12</sup>,  
(CH<sub>2</sub>)<sub>n</sub>N(CH<sub>2</sub>CONH<sub>2</sub>)COOR<sup>11</sup>, (CH<sub>2</sub>)<sub>n</sub>N(CH<sub>2</sub>CONH<sub>2</sub>)CONH<sub>2</sub>,  
(CH<sub>2</sub>)<sub>n</sub>CHR<sup>13</sup>COR<sup>11</sup>, (CH<sub>2</sub>)<sub>n</sub>CHR<sup>13</sup>COOR<sup>11</sup>,  
(CH<sub>2</sub>)<sub>n</sub>CHR<sup>13</sup>CH<sub>2</sub>OR<sup>14</sup>, (CH<sub>2</sub>)<sub>n</sub>OCN and (CH<sub>2</sub>)<sub>n</sub>NCO, wherein

R<sup>11</sup>, R<sup>12</sup> are independently selected from a the group consisting of H, A,  
(CH<sub>2</sub>)<sub>m</sub>Ar<sup>3</sup> and (CH<sub>2</sub>)<sub>m</sub>Het, or in NR<sup>11</sup>R<sup>12</sup>,

R<sup>11</sup> and R<sup>12</sup> form, together with the N-atom they are bound to, a 5-, 6- or  
7-membered heterocyclic heterocycle which optionally contains  
1 or 2 additional heteroatoms, selected from the group consisting  
of N, O and S,

R<sup>13</sup>, R<sup>14</sup> are independently selected from a the group consisting of H, Hal,  
A, (CH<sub>2</sub>)<sub>m</sub>Ar<sup>4</sup> and (CH<sub>2</sub>)<sub>m</sub>Het,

Ar<sup>3</sup>, Ar<sup>4</sup> are independently from one another aromatic hydrocarbon  
residues comprising 5 to 12 and preferably 5 to 10 carbon atoms  
which are optionally substituted by one or more substituents,  
selected from a the group consisting of A, Hal, NO<sub>2</sub>, CN, OR<sup>15</sup>,

NR<sup>15</sup>R<sup>16</sup>, COOR<sup>15</sup>, CONR<sup>15</sup>R<sup>16</sup>, NR<sup>15</sup>COR<sup>16</sup>, NR<sup>15</sup>CONR<sup>15</sup>R<sup>16</sup>,  
NR<sup>16</sup>SO<sub>2</sub>A, COR<sup>15</sup>, SO<sub>2</sub>R<sup>15</sup>R<sup>16</sup>, S(O)<sub>u</sub>A and OOCR<sup>15</sup>,

Het is a saturated, unsaturated or aromatic heterocyclic residue which is optionally substituted by one ~~ore~~ or more substituents selected from a the group consisting of A, Hal, NO<sub>2</sub>, CN, OR<sup>15</sup>, NR<sup>15</sup>R<sup>16</sup>, COOR<sup>15</sup>, CONR<sup>15</sup>R<sup>16</sup>, NR<sup>15</sup>COR<sup>16</sup>, NR<sup>15</sup>CONR<sup>15</sup>R<sup>16</sup>, NR<sup>16</sup>SO<sub>2</sub>A, COR<sup>15</sup>, SO<sub>2</sub>R<sup>15</sup>R<sup>16</sup>, S(O)<sub>u</sub>A and OOCR<sup>15</sup>,

R<sup>15</sup>, R<sup>16</sup> are independently selected from a the group consisting of H, A, and (CH<sub>2</sub>)<sub>m</sub>Ar<sup>6</sup>, wherein

Ar<sup>6</sup> is a 5- or 6-membered aromatic hydrocarbon which is optionally substituted by one or more substituents selected from a the group consisting of methyl, ethyl, propyl, 2-propyl, tert.-butyl, Hal, CN, OH, NH<sub>2</sub> and CF<sub>3</sub>,

k, m and n are independently of one another 0, 1, 2, 3, 4, or 5,

X represents a bond or is (CR<sup>11</sup>R<sup>12</sup>)<sub>h</sub>, or (CHR<sup>11</sup>)<sub>h</sub>-Q-(CHR<sup>12</sup>)<sub>i</sub>, wherein

Q is selected from a the group consisting of O, S, N-R<sup>15</sup>, (CHal<sub>2</sub>)<sub>j</sub>, (O-CHR<sup>18</sup>)<sub>j</sub>, (CHR<sup>18</sup>-O)<sub>j</sub>, CR<sup>18</sup>=CR<sup>19</sup>, (O-CHR<sup>18</sup>CHR<sup>19</sup>)<sub>j</sub>, (CHR<sup>18</sup>CHR<sup>19</sup>-O)<sub>j</sub>, C=O, C=S, C=NR<sup>15</sup>, CH(OR<sup>15</sup>), C(OR<sup>15</sup>)(OR<sup>20</sup>), C(=O)O, OC(=O), OC(=O)O, C(=O)N(R<sup>15</sup>), N(R<sup>15</sup>)C(=O), OC(=O)N(R<sup>15</sup>), N(R<sup>15</sup>)C(=O)O, CH=N-O, CH=N-NR<sup>15</sup>, S=O, SO<sub>2</sub>, SO<sub>2</sub>NR<sup>15</sup> and NR<sup>15</sup>SO<sub>2</sub>, wherein

$R^{18}$ ,  $R^{19}$ ,  $R^{20}$  are independently selected from the group consisting of the meanings given for  $R^8$ ,  $R^9$  and  $R^{10}$ , preferably independently selected from the group consisting of H, A, Hal,  $CH_2Hal$ ,  $CH(Hal)_2$ ,  $C(Hal)_3$ ,  $NO_2$ ,  $(CH_2)_nCN$ ,  $(CH_2)_nOR^{11}$ ,  $(CH_2)_nNR^{11}R^{12}$ ,  $(CH_2)_nO(CH_2)_kNR^{11}R^{12}$ ,  $(CH_2)_nCOOR^{13}$ ,  $(CH_2)_nCONR^{11}R^{12}$ ,  $(CH_2)_nNR^{11}COR^{13}$ ,  $(CH_2)_nNR^{11}CONR^{11}R^{12}$ ,  $(CH_2)_nNR^{11}SO_2A$ ,  $(CH_2)_nSO_2NR^{11}R^{12}$ ,  $(CH_2)_nS(O)_uR^{13}$ ,  $(CH_2)_nCOR^{13}$ ,  $(CH_2)_nSR^{14}$ ,  $(CH_2)_nNHOA$  and  $(CH_2)_nNR^{11}COOR^{13}$ ,

h, i are independently from each other 0, 1, 2, 3, 4, 5, or 6, and

j is 1, 2, 3, 4, 5, or 6,

Y is selected from the group consisting of O, S,  $NR^{21}$ ,  $C(R^{22})-NO_2$ ,  $C(R^{22})-CN$  and  $C(CN)_2$ , wherein

$R^{21}$  is independently selected from the meanings given for  $R^{13}$ ,  $R^{14}$  and

$R^{22}$  is independently selected from the meanings given for  $R^{11}$ ,  $R^{12}$ ,

p, r are independently from one another 0, 1, 2, 3, 4 or 5,

q is 0, 1, 2, 3 or 4, preferably 0, 1 or 2,

u is 0, 1, 2 or 3, preferably 0, 1 or 2,

and

Hal is independently selected from a the group consisting of F, Cl, Br and I; or

the tautomeric forms, thereof, and the pharmaceutically acceptable derivatives, solvates, salts, and stereoisomers thereof or mixtures thereof in all ratios.

2. (Currently Amended) Benzimidazole carboxamide The compound or compounds according to claim 1, wherein

Ar<sup>2</sup> is selected from aromatic hydrocarbons containing 6 to 10 and especially 6 carbon atoms and ethylenical unsaturated or aromatic heterocyclic residues containing 3 to 8 and especially 4 to 6 carbon atoms and one or two heteroatoms, independently selected from the group consisting of N, O and S and especially selected from N and O,

R<sup>8</sup>, R<sup>9</sup> and R<sup>10</sup> are independently selected from a the group consisting of H, A, cycloalkyl comprising 3 to 7 carbon atoms, Hal, CH<sub>2</sub>Hal, CH(Hal)<sub>2</sub>, C(Hal)<sub>3</sub>, NO<sub>2</sub>, (CH<sub>2</sub>)<sub>n</sub>CN, (CH<sub>2</sub>)<sub>n</sub>OR<sup>11</sup>, (CH<sub>2</sub>)<sub>n</sub>NR<sup>11</sup>R<sup>12</sup>, (CH<sub>2</sub>)<sub>n</sub>O(CH<sub>2</sub>)<sub>k</sub>NR<sup>11</sup>R<sup>12</sup>, (CH<sub>2</sub>)<sub>n</sub>COOR<sup>13</sup>, (CH<sub>2</sub>)<sub>n</sub>CONR<sup>11</sup>R<sup>12</sup>, (CH<sub>2</sub>)<sub>n</sub>NR<sup>11</sup>COR<sup>13</sup>, (CH<sub>2</sub>)<sub>n</sub>NR<sup>11</sup>CONR<sup>11</sup>R<sup>12</sup>, (CH<sub>2</sub>)<sub>n</sub>NR<sup>11</sup>SO<sub>2</sub>A, (CH<sub>2</sub>)<sub>n</sub>SO<sub>2</sub>NR<sup>11</sup>R<sup>12</sup>, (CH<sub>2</sub>)<sub>n</sub>S(O)<sub>u</sub>R<sup>13</sup>, (CH<sub>2</sub>)<sub>n</sub>OC(O)R<sup>13</sup>, (CH<sub>2</sub>)<sub>n</sub>COR<sup>13</sup>, (CH<sub>2</sub>)<sub>n</sub>SR<sup>11</sup>, (CH<sub>2</sub>)<sub>n</sub>NHOA, (CH<sub>2</sub>)<sub>n</sub>NR<sup>11</sup>COOR<sup>13</sup>, (CH<sub>2</sub>)<sub>n</sub>N(R<sup>11</sup>)CH<sub>2</sub>CH<sub>2</sub>OR<sup>13</sup>, (CH<sub>2</sub>)<sub>n</sub>N(R<sup>11</sup>)CH<sub>2</sub>CH<sub>2</sub>OCF<sub>3</sub>, (CH<sub>2</sub>)<sub>n</sub>N(R<sup>11</sup>)C(R<sup>13</sup>)HCOOR<sup>8</sup>, (CH<sub>2</sub>)<sub>n</sub>N(R<sup>11</sup>), C(R<sup>13</sup>)HCOR<sup>8</sup>, (CH<sub>2</sub>)<sub>n</sub>N(COOR<sup>13</sup>)COOR<sup>14</sup>, (CH<sub>2</sub>)<sub>n</sub>N(CONH<sub>2</sub>)COOR<sup>13</sup>, (CH<sub>2</sub>)<sub>n</sub>N(CONH<sub>2</sub>)CONH<sub>2</sub>, (CH<sub>2</sub>)<sub>n</sub>N(CH<sub>2</sub>COOR<sup>13</sup>)COOR<sup>14</sup>, (CH<sub>2</sub>)<sub>n</sub>N(CH<sub>2</sub>CONH<sub>2</sub>)COOR<sup>13</sup>, (CH<sub>2</sub>)<sub>n</sub>N(CH<sub>2</sub>CONH<sub>2</sub>)CONH<sub>2</sub>,

$(CH_2)_nCHR^{13}COR^{14}$ ,  $(CH_2)_nCHR^{13}COOR^{14}$  and  
 $(CH_2)_nCHR^{13}CH_2OR^{14}$ ,

X           represents a bond or is  $(CR^{11}R^{12})_h$ , or  $(CHR^{11})_h-Q-(CHR^{12})_i$ ,  
wherein

Q           is selected from a the group consisting of O, S, N-R<sup>15</sup>, (CHal<sub>2</sub>)<sub>j</sub>,  
 $(O-CHR^{18})_j$ ,  $(CHR^{18}-O)_j$ ,  $CR^{18}=CR^{19}$ ,  $(O-CHR^{18}CHR^{19})_j$ ,  
 $(CHR^{18}CHR^{19}-O)_j$ , C=O, C=NR<sup>15</sup>, CH(OR<sup>15</sup>), C(OR<sup>15</sup>)(OR<sup>20</sup>),  
C(=O)N(R<sup>15</sup>), N(R<sup>15</sup>)C(=O), CH=N-NR<sup>15</sup>, S=O, SO<sub>2</sub>, SO<sub>2</sub>NR<sup>15</sup>  
and NR<sup>15</sup>SO<sub>2</sub>, wherein

h, i       are independently from each other 0, 1, 2, 3, 4, 5 or 6, preferably  
0, 1, 2 or 3 and





j           is 1, 2, 3, 4, 5 or 6, preferably 1, 2, 3 or 4,

p           is 1, 2, 3 or 4, preferably 1, 2 or 3, and

r           is 0, 1, 2, or 3, preferably 0, 1 or 2;

~~the tautomeric forms thereof; and the pharmaceutically acceptable derivatives, solvates, salts and stereoisomers thereof.~~

3. (Currently Amended) Benzimidazole carboxamide The compound or compounds according to claim 1, selected from the group consisting of the compounds of the formulae Ia, Ib, Ic and Id,



wherein

$R^8$ , p, X, Y,  $R^9$  and q are as defined in claim 1, and  $R^{10}$  is H or as defined in claim 1;

~~the tautomeric forms thereof, and the pharmaceutically acceptable derivatives, solvates, salts and stereoisomers thereof.~~

4. (Currently Amended) ~~Benzimidazole carboxamide~~ The compound or compounds according to claim 3, additionally comprising one or two substituents selected from the group consisting of  $O(CH_2)_nNR^{11}R^{12}$ ,  $NR^{11}(CH_2)_nNR^{11}R^{12}$ ,  $O(CH_2)_nOR^{12}$  and  $NR^{11}(CH_2)_nOR^{12}$ ,

wherein

$R^{11}, R^{12}$  are independently selected from a the group consisting of H, A,  $(CH_2)_mAr^3$  and  $(CH_2)_mHet$ , or in  $NR^{11}R^{12}$ ,

$R^{11}$  and  $R^{12}$  form, together with the N-atom they are bound to, a 5-, 6- or 7-membered heterocyclic heterocycle which said heterocycle optionally contains 1 or 2 additional heteroatoms, selected from the group consisting of N, O and S, and  
 $n$  is 1, 2, 3, 4, 5 or 6.

5. (Currently Amended) ~~Benzimidazole carboxamide~~ The compound or compounds according to claim 1, selected from the group consisting of the compounds (1) to (128) of table 1; ~~the tautomeric forms, thereof, and the pharmaceutically acceptable derivatives, solvates, salts, and stereoisomers thereof and mixtures thereof in all ratios.~~

6. (Currently Amended) ~~Benzimidazole carboxamide~~ The compound or compounds according to claim 1 as a medicament.


7. (Currently Amended) ~~Benzimidazole carboxamide~~ The compound or compounds according to claim 1 as a kinase inhibitor.

8. (Currently Amended) Benzimidazole-carboxamide The compound or compounds according to claim 7, characterized in that the kinases are selected from the group consisting of raf-kinases and VEGFR kinases.
9. (Currently Amended) A pharmaceutical Pharmaceutical composition, characterized in that it contains comprising one or more of the compound or compounds according to claim 1.
10. (Currently Amended) The pharmaceutical Pharmaceutical composition according to claim 9, characterised characterized in that it contains one or more additional compounds, selected from the group consisting of physiologically acceptable excipients, auxiliaries, adjuvants, carriers and pharmaceutical active ingredients.
11. (Currently Amended) Process A process for the manufacture of a pharmaceutical composition, characterised comprising in that one or more of the compound or compounds according to claim 1 and one or more compound or compounds, selected from the group consisting of carriers, excipients, auxiliaries and pharmaceutical active ingredients other than the compound or compounds according to claim 1, is processed by mechanical means into a pharmaceutical composition that is suitable as dosage form for application and/or administration to a patient.
12. (Currently Amended) Use A method of comprising administering to a patient a the compound or compounds according to claim 1 as a pharmaceutical.
13. (Currently Amended) Use A method of comprising administering to a patient a the compound or compounds according to claim 1 in the treatment and/or prophylaxis of a disorder or disorders.

14. (Cancelled)
15. (Currently Amended) Use according to The method of claim 13, characterised characterized in that the disorder or disorders are caused, mediated and/or propagated by kinases selected from the group consisting of raf-kinases and VEGFR kinases.
16. (Currently Amended) Use according to The method of claim 13, characterised characterized in that the disorder or disorders are selected from the group consisting of hyperproliferative and nonhyperproliferative disorders.
17. (Currently Amended) Use according to The method of claim 13, characterised characterized in that the disorder or disorders is cancer.
18. (Currently Amended) Use according to The method of claim 13, characterised characterized in that the disorder or disorders is noncancerous.
19. (Currently Amended) Use according to The method of claim 18, characterised characterized in that the noncancerous disorder or disorders are selected from the group consisting of infections, psoriasis, arthritis, inflammation, endometriosis, scarring, benign prostatic hyperplasia, immunological diseases, autoimmune diseases and immunodeficiency diseases.

20. (Currently Amended) Use according to The method of claim 17, characterised characterized in that the disorder or disorders are selected from the group consisting of brain cancer, lung cancer, squamous cell cancer, bladder cancer, gastric cancer, pancreatic cancer, hepatic cancer, renal cancer, colorectal cancer, breast cancer, head cancer, neck cancer, oesophageal cancer, gynaecological cancer, thyroid cancer, lymphoma, chronic leukaemia and acute leukaemia.
21. (Currently Amended) Use according to The method of claim 13, characterised characterized in that the disorder or disorders are selected from the group consisting of arthritis, restenosis; fibrotic disorders; mesangial cell proliferative disorders, diabetic nephropathy, malignant nephrosclerosis, thrombotic microangiopathy syndromes, organ transplant rejection, glomerulopathies, metabolic disorders, inflammation and neurodegenerative diseases.
22. (Currently Amended) Use according to The method of claim 13, characterised characterized in that the disorder or disorders are selected from the group consisting of rheumatoid arthritis, inflammation, autoimmune disease, chronic obstructive pulmonary disease, asthma, inflammatory bowel disease, fibrosis, atherosclerosis, restenosis, vascular disease, cardiovascular disease, inflammation, renal disease and angiogenesis disorders.
23. (Currently Amended) Use A method of treatment comprising administering to a patient a the compound or compounds according to claim 1 as a kinase inhibitor.
24. (Currently Amended) Use according to The method of claim 23, characterised characterized in that the kinase is one or more raf-kinases, selected from the group consisting of A-Raf, B-Raf and Raf-1.

25. (Currently Amended) Method for the treatment and/or prophylaxis of disorders  
The method of claim 13, characterised characterized in that one or more of the compound or compounds according to claim 1 is administered to a patient in need of such a treatment.
26. (Currently Amended) Method according to The method of claim 25, characterised characterized in that the one or more of the compound or compounds according to one of the claims claim 1 to 5 are administered to the patient as a pharmaceutical composition.
27. (Currently Amended) Method for the treatment and/or prophylaxis of disorders according to The method of claim 26, characterised characterized in that the disorder or disorders are caused, mediated and/or propagated by kinases selected from the group consisting of raf-kinases and VEGFR kinases.
28. (Currently Amended) Method for the treatment according to The method of claim 27 17, characterised characterized in that the disorder or disorders is cancerous cell growth mediated by by one or more kinases.
29. (Currently Amended) Method A method for producing the compound or compounds of formula I claim 1, characterised in comprising that
- a) a compound of formula II




wherein

$L^1$  is Cl, Br, I, OH, an esterified OH-group or a diazonium moiety, and  
 $R^6, R^8, p$  and  $Y$  are as defined in claim 1,

is reacted

- b) with a compound of formula III,



wherein

$L^2$  is H or a metal ion, and  $R^7, R^9, q, X, Ar^2, R^{10}$  and  $r$  are as defined in claim 1,

and optionally

- c) isolating and/or treating the compound or compounds of claim 1 of formula I obtained by said reaction with an acid, to obtain the salt thereof.


30. (Currently Amended) Compound A compound or compounds of formula II,



wherein

$L^1$  is Cl, Br, I, OH, an esterified OH-group or a diazonium moiety, and  $R^6$ ,  $R^8$ , p and Y are as defined in claim 1.

31. (Currently Amended) Compound A compound or compounds of formula III,



wherein

$L^2$  is H or a metal ion, and  $R^7$ ,  $R^9$ , q, X,  $Ar^2$ ,  $R^{10}$  and r are as defined in claim 1.